Portfolio

We are enabling companies to turn their boldest ambitions into world-changing breakthroughs in healthcare and technology.

Portfolio

Spotlights Portfolio List

Portfolio List

Explores Glia's role in brain disease, acquired by Neumora.
Acquired by Neumora
Develops nausea treatments for surgical and cancer patients.
Acquired by Eagle Pharmaceuticals / EURONEXT: ACPH
Develops protein conjugate therapies, combining biologics and small molecule payloads to treat cancer.
Developing a protein nanoparticle (PNP) delivery platform.
Develops transformative gene therapies for devastating diseases using rationally designed AAV vectors.
Was a leading wireless networking company with AireWave Director software; acquired by Cisco in 2005.
Acquired by Cisco
AI-powered R&D platform for chemistry and materials science.
Develops targeted radioligand therapies (RLTs) to improve cancer treatment globally.
Develops precision medicines targeting protein synthesis for breakthrough cancer therapies.
Mobile advertising measurement platform for real-time user acquisition campaign analysis.
Develops alpha radioligand therapies (ARTs) for targeted cancer treatment with resilient supply chain.
Developed Ontozry™ (cenobamate) to treat epilepsy.
Acquired by Angelini Pharma
All-in-one recruiting platform for high-growth companies, combining features with advanced analytics.
Developing neurodegenerative disease treatments using proprietary RNA interference platform.
Develops improved therapies for idiopathic pulmonary fibrosis (IPF) and other respiratory diseases.
Develops CAR-T cell therapies using switchable and scalable platforms for cancers.
Pioneering gene therapy company focused on transformative medicines for neurodegenerative disorders.
Focuses on developing therapies for diseases of the eye.
Acquired by Shire
Developing base editing technology for a range of applications.
Secures and manages open source software worldwide.
Acquired by Synopsys
Modernizes hotel operations with its mobile web Guest Management System globally.
Provides affordable, convenient, and effective orthodontic solutions through clear aligners and remote monitoring.
Rapidly growing pharmaceutical company focusing on emerging markets and expanding into regulated markets.
Developed lixivaptan for hyponatremia treatment.
Acquired by Cornerstone Therapeutics
Zero-configuration solution for account takeover (ATO) protection.
Employs DragonFold technology for rapid protein/ligand co-folding to develop novel drugs.
Immune-activating cancer therapy company acquired by Regeneron in 2022, developed vidutolimod.
Acquired by Regeneron / NASDAQ: CMPI
Develops and commercializes consumer healthcare and over-the-counter products.
Scalable NoSQL Database-as-a-Service for modern applications
Acquired by IBM
Cloud-based CI/CD testing platform.
Acquired by Cloudbees
Developing the first therapy targeting a root cause of preterm preeclampsia to reduce risks for mothers and babies, including premature birth.
Leader in discovery and development of novel drugs in stem cell related diseases.
Seed-stage venture firm and accelerator for therapeutics startups, providing expertise and capital.
Global, comprehensive POI datasets.
AI to automate traditionally manual processes in travel.
AAV gene therapy developer for rare diseases.
Acquired by Ultragenyx Pharmaceuticals
Developing curative medicines through precision in vivo cellular engineering.
Specializing in biosimilars and novel biologics for global healthcare markets.
Focused on affordable, high-quality medicines for patients worldwide.
Developing small molecule therapeutics for protein misfolding and aggregation diseases.
Acquired by Pfizer
Automating collection, storage, and analysis of advertising data.
Improving diagnostic testing and accelerate drug discovery in diverse underserved populations.
Offering geospatial network data for infrastructure planning and analysis.
Acquired by Cisco Systems
Offers live, expert-led classes for managers and emerging leaders through a professional development platform.
Leading provider of enterprise contract management software using AI to optimize business processes.
Developing Midazolam Nasal Spray (USL261) for acute repetitive seizures.
Acquired by UCB
Leading the change in cell & gene therapies & personalized immunotherapy.
Dedicated to developing novel treatments for fibrotic diseases.
Harnessing deep learning to accelerate pharmaceutical development.
Developing novel protein-based therapeutics for companion animals.
Acquired by Dechra
Developing novel treatments for unmet medical needs.
Targets epigenetic pathways to develop innovative cancer therapies.
Simplifies lead management and sales prospecting.
Developing nasal spray products to prevent respiratory viruses.
Leading commercial platform for the travel & hospitality industry.
Developing innovative vaccines for the prevention of gastrointestinal diseases.
Acquired by Takeda
Provides visibility and collaboration tools for logistics companies though digital freight forwarding.
Bringing cell-based therapies to heart failure patients.
Offering cloud, data center, and managed IT solutions.
Acquired by Roche Company
Develops targeted therapies for rare genetic diseases and mitochondrial disorders.
Acquired by Zogenix
Uses AI-powered insights for personalized marketing campaigns to drive customer engagement.
Building human-embodied intelligence to empower humans.
Building intelligent applications and machine learning solutions.
Creates and promotes differentiated products in the pediatric market.
Acquired by Pfizer
Develops targeted therapies for fibrotic diseases and other dermatological conditions.
Developing novel therapeutics for neurogenic cough and inflammation.
Developing small molecule inhibitors of the NLRP3 inflammasome.
Develops innovative therapies to address unmet medical needs in various diseases.
Acquired by SciClone
Provides cybersecurity and data leakage prevention systems.
Acquired by Raytheon
Offers backup, recovery, and compliance solutions for Salesforce through enterprise data protection.
Accelerating the advancement of globally competitive oncology assets for patients.
Developing treatments for rare diseases using bone-marrow gene therapy.
NASDAQ: ORTX
Enables collaboration for secure file sharing, data privacy, and remote access.
Acquired by Kiteworks
Offers clean-label wellness supplements for health-conscious consumers through plant-based nutrition.
Developing and introducing effective and clinically proven children's medicines for China.
Designing novel therapeutics against previously undruggable targets using experimental and computational biophysics.
Automated visual testing for web and mobile interfaces.
Acquired by BrowserStack
Provides secure, seamless authentication and access management solutions.
Acquired by Vista Equity Partners
Developing and supplying plasma protein therapies for the treatment of rare and chronic diseases.
Developing therapies for neuropsychiatric and neurodevelopmental disorders.
Protect patient data and prevent privacy breaches through healthcare compliance.
Acquired by Bluesight
Developing therapies targeting protein misfolding diseases.
Merged with Yumanity Therapeutics in 2020
Developing inhaled therapies for severe respiratory infections and lung conditions.
Developing and commercializing therapies for rare diseases in Asia.
Platform for managing API documentation and developer hubs.
Subscription management and billing platform for recurring revenue businesses
Acquired by Accel-KKR
Developing innovative inhaled therapies for severe respiratory diseases.
Acquired by Centocor Ortho Biotech
Developing gene therapies for retinal diseases causing blindness.
Developing RNA-based therapeutics for immune modulation and viral defense.
Risklens is a cyber risk analytics platform helping businesses quantify and manage financial risk.
Acquired by Safe Security
Assesses third-party vendor risks through automated security analysis.
Acquired by Mastercard
Evaluation, testing, and simulation platform for voice agents.
Discovering and developing novel first-in-class small molecule drugs with the potential to address multiple psychiatric indications.
Leveraging machine learning for threat detection and response.
Acquired by Vista Equity Partners
Developing cell therapies for treating type 1 diabetes.
Acquired by Vertex
Developing therapies that target aging at the cellular level.
Pioneering novel immunotherapies for cancer treatment.
Facilitating data-driven life science research and empowering drug R&D processes.
Revolutionizing global shipping with transparent pricing, real-time tracking, and eco-friendly solutions.
Enables personalized marketing campaigns through data unification.
Developing treatments for age-related degenerative diseases.
Developing innovative treatments for genetic diseases through gene therapy.
Developing next-generation antibody therapies focused on the tumor microenvironment.
NASDAQ:SURF
Developing innovative treatments for women’s health conditions.
Advancing TCR bispecific therapies for cancer and autoimmune disorders.
Transforming global drug discovery with advanced AI and physics-based technologies.
Developing a novel therapy to treat presbyopia.
Improving the lives of patients and caregivers impacted by neurological, cardiometabolic, and ophthalmic diseases.
Developing antibiotics for multi-drug-resistant infections.
NASDAQ: TTPH
Providing real-time threat detection and risk management though cloud security.
Acquired by F5 Networks
Developing treatments for pediatric infectious diseases.
Acquired by Sanofi
Developing inhaled therapies for respiratory and lung infections.
Acquired by Insmed Inc.
Offers customized itineraries, booking tools, and trip management solutions.
Enhances product discovery with personalized search and recommendations through AI-driven e-commerce.
Acquired by Netcore Cloud
Helps businesses buy and manage software efficiently.
Ensures secure digital transactions through biometric authentication.
Acquired by EMC
Developing treatments for dermatological conditions like rosacea.
Acquired by Allergan
Enables personalized networking and relationship-building for professionals.
Helps users navigate software through interactive guidance and support.
The companies identified do not represent all the companies purchased, sold, or recommended for portfolios advised by F-Prime.